Predictors* of good clinical response to adalimumab at week 12, as defined by ACR50 and good response according to EULAR criteria
| Predictors | ACR50 response | Good response according to EULAR criteria | ||
| OR (95% CI) | p Value | OR (95% CI) | p Value | |
| Sex (male vs female) | 1.77 (1.12 to 2.79) | 0.014 | 2.24 (1.39 to 3.59) | <0.001 |
| HAQ-DI (per unit) | 0.39 (0.25 to 0.60) | <0.001 | 0.54 (0.35 to 0.85) | 0.007 |
| Systemic glucocorticoids (⩽10 mg/day)† | 0.57 (0.35 to 0.92) | 0.022 | 0.53 (0.32 to 0.88) | 0.014 |
| Patient’s assessment of pain (per 0–100 mm VAS unit) | 1.02 (1.01 to 1.03) | 0.003 | 1.01 (1.00 to 1.03) | 0.027 |
| C-reactive protein (per mg/dl) | 1.15 (1.01 to 1.30) | 0.035 | – | – |
| Swollen joint count (0–76; ⩾5 vs <5) | 2.11 (1.13 to 3.94) | 0.019 | – | – |
| ⩾1 Inflamed large joint†‡ | – | – | 0.55 (0.34 to 0.89) | 0.015 |
| Treatment with SSZ† | – | – | 3.11 (1.35 to 7.12) | 0.007 |
| Prior DMARD use (⩾2 vs <2) | – | – | 1.79 (1.08 to 2.96) | 0.024 |
*For identification of predictors of ACR50 and good responses according to EULAR criteria, the ensemble of all potential factors was investigated by logistic regression with backward elimination (selection level, 5%); †yes vs no; ‡“large joint” could include the shoulder, elbow, knee, or hip.
ACR50, American College of Rheumatology response criteria, 50% improvement; DMARD, disease-modifying antirheumatic drug; EULAR, European League Against Rheumatism; HAQ-DI, Health Assessment Questionnaire Disability Index; OR, odds ratio; PsA, psoriatic arthritis; SSZ, sulfasalazine; VAS, visual analogue scale.